---
title: Tumour-informed liquid biopsies to monitor advanced melanoma patients under
  immune checkpoint inhibition
date: '2024-10-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39384805/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241010184200&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Immune checkpoint inhibitors (ICI) have significantly improved overall
  survival in melanoma patients. However, 60% experience severe adverse events and
  early response markers are lacking. Circulating tumour DNA (ctDNA) is a promising
  biomarker for treatment-response and recurrence detection. The prospective PET/LIT
  study included 104 patients with palliative combined or adjuvant ICI. Tumour-informed
  sequencing panels to monitor 30 patient-specific variants were designed and 321
  liquid ...
disable_comments: true
---
Immune checkpoint inhibitors (ICI) have significantly improved overall survival in melanoma patients. However, 60% experience severe adverse events and early response markers are lacking. Circulating tumour DNA (ctDNA) is a promising biomarker for treatment-response and recurrence detection. The prospective PET/LIT study included 104 patients with palliative combined or adjuvant ICI. Tumour-informed sequencing panels to monitor 30 patient-specific variants were designed and 321 liquid ...